Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

El-Galaly, TC, Cheah, CY, Bendtsen, MD, Nowakowski, GS, Kansara, R, Savage, KJ, Connors, JM, Sehn, LH, Goldschmidt, N, Shaulov, A, Farooq, U, Link, BK, Ferreri, AJM, Calimeri, T, Cecchetti, C, Dann, EJ, Thompson, CA, Inbar, T, Maurer, MJ, Gade, IL, Juul, MB, Hansen, JW, Holmberg, S, Larsen, TS, Cordua, S, Mikhaeel, NG, Hutchings, M, Seymour, JF, Clausen, MR, Smith, D, Opat, S, Gilbertson, M, Thanarajasingam, G & Villa, D 2018, 'Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma' European journal of cancer (Oxford, England : 1990), vol. 93, pp. 57-68. https://doi.org/10.1016/j.ejca.2018.01.073

APA

CBE

El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, Connors JM, Sehn LH, Goldschmidt N, Shaulov A, Farooq U, Link BK, Ferreri AJM, Calimeri T, Cecchetti C, Dann EJ, Thompson CA, Inbar T, Maurer MJ, Gade IL, Juul MB, Hansen JW, Holmberg S, Larsen TS, Cordua S, Mikhaeel NG, Hutchings M, Seymour JF, Clausen MR, Smith D, Opat S, Gilbertson M, Thanarajasingam G, Villa D. 2018. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. European journal of cancer (Oxford, England : 1990). 93:57-68. https://doi.org/10.1016/j.ejca.2018.01.073

MLA

Vancouver

Author

El-Galaly, Tarec Christoffer ; Cheah, Chan Yoon ; Bendtsen, Mette Dahl ; Nowakowski, Grzegorz S ; Kansara, Roopesh ; Savage, Kerry J ; Connors, Joseph M ; Sehn, Laurie H ; Goldschmidt, Neta ; Shaulov, Adir ; Farooq, Umar ; Link, Brian K ; Ferreri, Andrés J M ; Calimeri, Teresa ; Cecchetti, Caterina ; Dann, Eldad J ; Thompson, Carrie A ; Inbar, Tsofia ; Maurer, Matthew J ; Gade, Inger Lise ; Juul, Maja Bech ; Hansen, Jakob W ; Holmberg, Staffan ; Larsen, Thomas S ; Cordua, Sabrina ; Mikhaeel, N George ; Hutchings, Martin ; Seymour, John F ; Clausen, Michael Roost ; Smith, Daniel ; Opat, Stephen ; Gilbertson, Michael ; Thanarajasingam, Gita ; Villa, Diego. / Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. In: European journal of cancer (Oxford, England : 1990). 2018 ; Vol. 93. pp. 57-68.

Bibtex

@article{9ee10eaa5bbf4e4c93819635f6b55d59,
title = "Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma",
abstract = "PURPOSE: Secondary CNS involvement (SCNS) is a profoundly adverse complication of diffuse large B-cell lymphoma. Evidence from older series indicated a median overall survival (OS) < 6 months; however, data from the immunochemotherapy era are limited.METHODS: Patients diagnosed with SCNS during or after first-line immunochemotherapy were identified from databases and/or regional/national registries from three continents. Clinical information was retrospectively collected from medical records.RESULTS: In total, 291 patients with SCNS were included. SCNS occurred as part of first relapse in 254 (87{\%}) patients and 113 (39{\%}) had concurrent systemic relapse. With a median post-SCNS follow-up of 48 months, the median post-SCNS OS was 3.9 months and 2-year OS rate was 20{\%} (95{\%} CI: 15-25). In multivariable analysis of 173 patients treated with curative/intensive therapy (such as high-dose methotrexate [HDMTX] or platinum-containing regimens), age ≤60 years, performance status 0-1, absence of combined leptomeningeal and parenchymal involvement, and SCNS occurring after completion of first-line therapy were associated with superior outcomes. Patients ≤60 years with performance status 0-1 and treated with HDMTX-based regimens for isolated parenchymal SCNS had a 2-year OS of 62{\%} (95{\%} CI: 36-80). In patients with isolated SCNS, the addition of rituximab to HDMTX-based regimens was associated with improved OS. Amongst patients with isolated SCNS in CR following intensive treatment, high-dose chemotherapy and autologous stem cell transplantation did not improve OS (P = 0.9).CONCLUSIONS: In this large international cohort of patients treated with first-line immunochemotherapy, outcomes following SCNS remain poor. However, a moderate proportion of patients with isolated SCNS who received intensive therapies achieved durable remissions.",
author = "El-Galaly, {Tarec Christoffer} and Cheah, {Chan Yoon} and Bendtsen, {Mette Dahl} and Nowakowski, {Grzegorz S} and Roopesh Kansara and Savage, {Kerry J} and Connors, {Joseph M} and Sehn, {Laurie H} and Neta Goldschmidt and Adir Shaulov and Umar Farooq and Link, {Brian K} and Ferreri, {Andr{\'e}s J M} and Teresa Calimeri and Caterina Cecchetti and Dann, {Eldad J} and Thompson, {Carrie A} and Tsofia Inbar and Maurer, {Matthew J} and Gade, {Inger Lise} and Juul, {Maja Bech} and Hansen, {Jakob W} and Staffan Holmberg and Larsen, {Thomas S} and Sabrina Cordua and Mikhaeel, {N George} and Martin Hutchings and Seymour, {John F} and Clausen, {Michael Roost} and Daniel Smith and Stephen Opat and Michael Gilbertson and Gita Thanarajasingam and Diego Villa",
note = "Copyright {\circledC} 2018 Elsevier Ltd. All rights reserved.",
year = "2018",
month = "4",
day = "1",
doi = "10.1016/j.ejca.2018.01.073",
language = "English",
volume = "93",
pages = "57--68",
journal = "European Journal of Cancer, Supplement",
issn = "0959-8049",
publisher = "Pergamon",

}

RIS

TY - JOUR

T1 - Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma

AU - El-Galaly, Tarec Christoffer

AU - Cheah, Chan Yoon

AU - Bendtsen, Mette Dahl

AU - Nowakowski, Grzegorz S

AU - Kansara, Roopesh

AU - Savage, Kerry J

AU - Connors, Joseph M

AU - Sehn, Laurie H

AU - Goldschmidt, Neta

AU - Shaulov, Adir

AU - Farooq, Umar

AU - Link, Brian K

AU - Ferreri, Andrés J M

AU - Calimeri, Teresa

AU - Cecchetti, Caterina

AU - Dann, Eldad J

AU - Thompson, Carrie A

AU - Inbar, Tsofia

AU - Maurer, Matthew J

AU - Gade, Inger Lise

AU - Juul, Maja Bech

AU - Hansen, Jakob W

AU - Holmberg, Staffan

AU - Larsen, Thomas S

AU - Cordua, Sabrina

AU - Mikhaeel, N George

AU - Hutchings, Martin

AU - Seymour, John F

AU - Clausen, Michael Roost

AU - Smith, Daniel

AU - Opat, Stephen

AU - Gilbertson, Michael

AU - Thanarajasingam, Gita

AU - Villa, Diego

N1 - Copyright © 2018 Elsevier Ltd. All rights reserved.

PY - 2018/4/1

Y1 - 2018/4/1

N2 - PURPOSE: Secondary CNS involvement (SCNS) is a profoundly adverse complication of diffuse large B-cell lymphoma. Evidence from older series indicated a median overall survival (OS) < 6 months; however, data from the immunochemotherapy era are limited.METHODS: Patients diagnosed with SCNS during or after first-line immunochemotherapy were identified from databases and/or regional/national registries from three continents. Clinical information was retrospectively collected from medical records.RESULTS: In total, 291 patients with SCNS were included. SCNS occurred as part of first relapse in 254 (87%) patients and 113 (39%) had concurrent systemic relapse. With a median post-SCNS follow-up of 48 months, the median post-SCNS OS was 3.9 months and 2-year OS rate was 20% (95% CI: 15-25). In multivariable analysis of 173 patients treated with curative/intensive therapy (such as high-dose methotrexate [HDMTX] or platinum-containing regimens), age ≤60 years, performance status 0-1, absence of combined leptomeningeal and parenchymal involvement, and SCNS occurring after completion of first-line therapy were associated with superior outcomes. Patients ≤60 years with performance status 0-1 and treated with HDMTX-based regimens for isolated parenchymal SCNS had a 2-year OS of 62% (95% CI: 36-80). In patients with isolated SCNS, the addition of rituximab to HDMTX-based regimens was associated with improved OS. Amongst patients with isolated SCNS in CR following intensive treatment, high-dose chemotherapy and autologous stem cell transplantation did not improve OS (P = 0.9).CONCLUSIONS: In this large international cohort of patients treated with first-line immunochemotherapy, outcomes following SCNS remain poor. However, a moderate proportion of patients with isolated SCNS who received intensive therapies achieved durable remissions.

AB - PURPOSE: Secondary CNS involvement (SCNS) is a profoundly adverse complication of diffuse large B-cell lymphoma. Evidence from older series indicated a median overall survival (OS) < 6 months; however, data from the immunochemotherapy era are limited.METHODS: Patients diagnosed with SCNS during or after first-line immunochemotherapy were identified from databases and/or regional/national registries from three continents. Clinical information was retrospectively collected from medical records.RESULTS: In total, 291 patients with SCNS were included. SCNS occurred as part of first relapse in 254 (87%) patients and 113 (39%) had concurrent systemic relapse. With a median post-SCNS follow-up of 48 months, the median post-SCNS OS was 3.9 months and 2-year OS rate was 20% (95% CI: 15-25). In multivariable analysis of 173 patients treated with curative/intensive therapy (such as high-dose methotrexate [HDMTX] or platinum-containing regimens), age ≤60 years, performance status 0-1, absence of combined leptomeningeal and parenchymal involvement, and SCNS occurring after completion of first-line therapy were associated with superior outcomes. Patients ≤60 years with performance status 0-1 and treated with HDMTX-based regimens for isolated parenchymal SCNS had a 2-year OS of 62% (95% CI: 36-80). In patients with isolated SCNS, the addition of rituximab to HDMTX-based regimens was associated with improved OS. Amongst patients with isolated SCNS in CR following intensive treatment, high-dose chemotherapy and autologous stem cell transplantation did not improve OS (P = 0.9).CONCLUSIONS: In this large international cohort of patients treated with first-line immunochemotherapy, outcomes following SCNS remain poor. However, a moderate proportion of patients with isolated SCNS who received intensive therapies achieved durable remissions.

U2 - 10.1016/j.ejca.2018.01.073

DO - 10.1016/j.ejca.2018.01.073

M3 - Journal article

VL - 93

SP - 57

EP - 68

JO - European Journal of Cancer, Supplement

JF - European Journal of Cancer, Supplement

SN - 0959-8049

ER -

ID: 54782366